Literature DB >> 15198464

Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications.

Lieuwe de Haan1, Jules Lavalaye, Marion van Bruggen, Lonneke van Nimwegen, Jan Booij, Therese van Amelsvoort, Don Linszen.   

Abstract

OBJECTIVES: This paper gives an overview of studies on the association between dopaminergic neurotransmission and the subjective experience of patients with schizophrenia.
METHODS: We undertook a review of the literature.
RESULTS: Dopaminergic neurotransmission may be relevant for subjective experience. Higher striatal D2 receptor occupancy by typical and atypical antipsychotics is related to worse subjective experience, more severe negative symptoms, and depression. Individuals with lower baseline dopamine function are at an increased risk for dysphoric responses during antipsychotic therapy with dopaminergic-blocking drugs. There is preliminary evidence that a window of striatal D2 receptor occupancy between 60% and 70% is optimal for the subjective experience of patients. These occupancies are often reached even with low dosages of antipsychotic drugs.
CONCLUSIONS: Reaching an optimal dopamine D2 receptor occupancy is clinically relevant, since subjective experience associated with antipsychotic medication is related to medication compliance. Antipsychotic drug dosages often need to be lower than levels in common use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198464     DOI: 10.1177/070674370404900503

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  20 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics.

Authors:  Georg Juckel; Florian Schlagenhauf; Michael Koslowski; Dimitri Filonov; Torsten Wüstenberg; Arno Villringer; Brian Knutson; Thorsten Kienast; Jürgen Gallinat; Jana Wrase; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2006-05-24       Impact factor: 4.530

3.  Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.

Authors:  Florian Schlagenhauf; Georg Juckel; Michael Koslowski; Thorsten Kahnt; Brian Knutson; Theresa Dembler; Thorsten Kienast; Jürgen Gallinat; Jana Wrase; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2007-12-21       Impact factor: 4.530

4.  Hyperactivation balances sensory processing deficits during mood induction in schizophrenia.

Authors:  Miriam Dyck; James Loughead; Ruben C Gur; Frank Schneider; Klaus Mathiak
Journal:  Soc Cogn Affect Neurosci       Date:  2012-10-10       Impact factor: 3.436

5.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

6.  Clozapine increases reward evaluation but not overall ingestive behaviour in rats licking for sucrose.

Authors:  Adriana Galistu; Cristina Modde; Maria Cristina Pireddu; Flavia Franconi; Gino Serra; Paolo S D'Aquila
Journal:  Psychopharmacology (Berl)       Date:  2011-03-01       Impact factor: 4.530

7.  Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

Authors:  Donald E Addington; Somaia Mohamed; Robert A Rosenheck; Sonia M Davis; Thomas Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2010-09-21       Impact factor: 4.384

8.  The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment.

Authors:  Michael E Ballard; Ana M Basso; Kelly B Gallagher; Kaitlin E Browman; Gerard B Fox; Karla U Drescher; Gerhard Gross; Michael W Decker; Lynne E Rueter; Min Zhang
Journal:  Psychopharmacology (Berl)       Date:  2006-11-09       Impact factor: 4.530

9.  Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings.

Authors:  Marco Pozzi; Dario Cattaneo; Sara Baldelli; Serena Fucile; Annalisa Capuano; Carmela Bravaccio; Liberata Sportiello; Silvana Bertella; Fabiana Auricchio; Renato Bernardini; Carmen Ferrajolo; Giuseppe Guastella; Elisa Mani; Carla Carnovale; Simone Pisano; Concetta Rafaniello; Maria Pia Riccio; Renata Rizzo; Maria Grazia Scuderi; Serena Sperandeo; Laura Villa; Antonio Pascotto; Massimo Molteni; Francesco Rossi; Sonia Radice; Emilio Clementi
Journal:  Eur J Clin Pharmacol       Date:  2015-11-28       Impact factor: 2.953

Review 10.  Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

Authors:  O D Howes; A Egerton; V Allan; P McGuire; P Stokes; S Kapur
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.